Omeros | OMER - Debt


Omeros reported $442.16M in Debt for its fiscal quarter ending in September of 2023.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Cytokinetics USD 858.06M 199.93M Jun/2025
Dynavax Technologies USD 285.5M 24.99M Jun/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Insmed USD 564.56M 464K Sep/2025
Knight Therapeutics CAD 106.24M 1.5M Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 376.72M 203.77M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025
Xoma USD 120.79M 3.27M Jun/2024